PF-03550096 is a drug that acts as a potent agonist for the CB2 cannabinoid receptor with good selectivity over CB1 having Ki values of 7nM at CB2 and 1500nM at CB1. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome but has only progressed to animal studies.
This page contains content from the copyrighted Wikipedia article "PF-03550096"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
